Our observations of a APOC3 LPL-independent triglyceride-related pathway agree with Gaudet et al,48 testing the effects of an APOC3 mRNA inhibitor on familial chylomicronemia syndrome sufferers. The gene discussed is LPL; the disease is familial chylomicronemia syndrome.